Study of Nimotuzumab to Treat Colorectal Cancer

Inclusion Criteria:

• Informed consent form signed before performing any of the study's specific procedures.
• ECOG performance status 0-2.
• Age > 18，both genders.
• Metastatic colorectal cancer confirmed by pathology, or locally advanced unresectable colorectal cancer, or postoperative recurrence and metastasis colorectal cancer
• Disease progression after receiving oxaliplatin ± fluorouracil in first-line treatment
• At least 1 measurable lesions ,( longest diameter≥ 1 cm by spiral computed tomography (CT) scan or MRI)
• Life expectancy more than 3 months.
• K-ras is wild type
• Use of an effective contraceptive method for patients of both sexes when there is a risk of conception and/or pregnancy.
• Liver metastasis, lesions smaller than 50% of the liver; Lung metastasis, lesions smaller than 30% of the lung
• Haemoglobin≥90g/L , granulocyte≥1.5×109/L ,WBC ≥3×109/L, platelet count≥100×109/L
• TBIL≤ 1.5 x ULN ,ALK≤ 2.5 x ULN or ≤ 5ULN（Liver metastasis），AST and ALT≤ 2.5 x ULN or ≤ 5ULN（Liver metastasis）,Creatinine ≤ 1.5 x ULN
• No brain metastasis

Exclusion Criteria:

• Previous radiotherapy at lesions within three months
• Other first line chemo-agents treatment except oxaliplatin ± fluorouracil
• Received other anti EGFR monoclonal antibody treatment
• Complete or incomplete intestinal obstruction
• Participation in other interventional clinical trials within 1 month
• Psychiatric disease affected cognitive ability, including brain metastasis
• Peripheral neuropathy lesion is more than I stage
• History of serious allergic or allergy
• Pregnant or breast-feeding women
• Patients with the history of Serious lung or hear disease
• Other malignant tumor